Vascular Biogenics Ltd. (VBLT) Q2 2019 Earnings Conference Call August 13, 2019 8:30 AM ET
Company Participants
Michael Wood – LifeSci Advisors
Dror Harats – Chief Executive Officer
Amos Ron – Chief Financial Officer
Conference Call Participants
Kevin DeGeeter – Oppenheimer
Geulah Livshits – Chardan
Sean Lee – H.C. Wainright
Sam Slutsky – LifeSci Capital
Soumit Roy – Jones Trading
Michael Wood
Thank you, operator. Good morning and thank you all for participating in today’s Second Quarter 2019 Results and Corporate Update Call for VBL Therapeutics. Leading the call today will be Professor Dror Harats, CEO of VBL; and Amos Ron, the company’s CFO.
A press release with the company’s financial results became available at 7:00 AM Eastern Time today and can be found on the Investors page of the company’s website at vblrx.com.
Before we begin, I’d like to remind everyone that various remarks about future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. VBL cautions that these forward-looking statements are the subject of risks and uncertainties that could cause actual results to differ materially from those indicated. Any forward-looking statements made on today’s conference call speaks only as of today’s date, Tuesday, August 13, 2019, and the company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after today’s date.
As a reminder, this conference call is being recorded and will be available for audio rebroadcast on the company’s website. As the operator mentioned, all participants are currently in listen-only mode and there will be a brief Q&A session following the company’s prepared remarks.
With that, I’d like to turn the call over to Professor Harats, CEO of VBL. Please go ahead.
Dror Harats
- Read more current VBLT analysis and news
- View all earnings call transcripts